HIF-2α inhibitor MK-6482 receives FDA Breakthrough Designation for Von Hippel-Lindau Disease-associated RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate, received Breakthrough Designation from FDA for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required.

HIF-2α inhibitor MK-6482 is sponsored by Merck.

FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a phase II trial evaluating MK-6482 in patients with VHL-associated clear cell RCC.

Table of Contents

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login